These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21304094)

  • 1. The impact of postrandomization crossover of therapy in acute coronary syndromes care.
    Mahaffey KW; Pieper KS; Lokhnygina Y; Califf RM; Antman EM; Kleiman NS; Goodman SG; White HD; Rao SV; Hochman JS; Cohen M; Col JJ; Roe MT; Ferguson JJ;
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):211-9. PubMed ID: 21304094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
    Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
    Cohen M; Mahaffey KW; Pieper K; Pollack CV; Antman EM; Hoekstra J; Goodman SG; Langer A; Col JJ; White HD; Califf RM; Ferguson JJ;
    J Am Coll Cardiol; 2006 Oct; 48(7):1346-54. PubMed ID: 17010793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
    Mahaffey KW; Tonev ST; Spinler SA; Levine GN; Gallo R; Ducas J; Goodman SG; Antman EM; Becker RC; Langer A; White HD; Aylward PE; Col JJ; Ferguson JJ; Califf RM;
    Int J Cardiol; 2010 Mar; 139(2):123-33. PubMed ID: 19012977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
    Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
    Lopes RD; Alexander KP; Marcucci G; White HD; Spinler S; Col J; Aylward PE; Califf RM; Mahaffey KW
    Eur Heart J; 2008 Aug; 29(15):1827-33. PubMed ID: 18519426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
    Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E;
    Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
    Chew DP; Huang Z; Pieper KS; White H; Mahaffey KW; Ferguson JJ; Califf RM; Aylward PG
    Am Heart J; 2008 Feb; 155(2):239-44. PubMed ID: 18215592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
    Tricoci P; Lokhnygina Y; Berdan LG; Steinhubl SR; Gulba DC; White HD; Kleiman NS; Aylward PE; Langer A; Califf RM; Ferguson JJ; Antman EM; Newby LK; Harrington RA; Goodman SG; Mahaffey KW
    Circulation; 2007 Dec; 116(23):2669-77. PubMed ID: 18025532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
    J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
    Ferguson JJ; Califf RM; Antman EM; Cohen M; Grines CL; Goodman S; Kereiakes DJ; Langer A; Mahaffey KW; Nessel CC; Armstrong PW; Avezum A; Aylward P; Becker RC; Biasucci L; Borzak S; Col J; Frey MJ; Fry E; Gulba DC; Guneri S; Gurfinkel E; Harrington R; Hochman JS; Kleiman NS; Leon MB; Lopez-Sendon JL; Pepine CJ; Ruzyllo W; Steinhubl SR; Teirstein PS; Toro-Figueroa L; White H;
    JAMA; 2004 Jul; 292(1):45-54. PubMed ID: 15238590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
    Montalescot G; White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    N Engl J Med; 2006 Sep; 355(10):1006-17. PubMed ID: 16957147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.
    Giraldez RR; Nicolau JC; Corbalan R; Gurfinkel EP; Juarez U; Lopez-Sendon J; Parkhomenko A; Molhoek P; Mohanavelu S; Morrow DA; Antman EM
    Eur Heart J; 2007 Jul; 28(13):1566-73. PubMed ID: 17562672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
    Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
    Santopinto J; Gurfinkel EP; Torres V; Marcos E; Bozovich GE; Mautner B; McCabe CH; Antman EM
    Am Heart J; 2001 Apr; 141(4):566-72. PubMed ID: 11275921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience.
    Schiele F; Meneveau N; Seronde MF; Descotes-Genon V; Dutheil J; Chopard R; Ecarnot F; Bassand JP;
    Am Heart J; 2010 Feb; 159(2):190-8. PubMed ID: 20152216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.